Loading…

Formulation of sustained release nanoparticles loaded with a tripentone, a new anticancer agent

The purpose of the present work is to develop nanoparticles of a new antitubulin agent of the family of tripentones by means of a phase inversion process. Dynamic light scattering, transmission electron microscopy and ζ-potential measurements were used to characterize tripentone loaded nanoparticles...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2006-08, Vol.320 (1), p.157-164
Main Authors: Malzert-Fréon, A., Vrignaud, S., Saulnier, P., Lisowski, V., Benoît, J.P., Rault, S.
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c424t-775089308f156c0bd49a6b3038a4150ef3844f4a27f4482aa5bdaca5e80e8d313
cites
container_end_page 164
container_issue 1
container_start_page 157
container_title International journal of pharmaceutics
container_volume 320
creator Malzert-Fréon, A.
Vrignaud, S.
Saulnier, P.
Lisowski, V.
Benoît, J.P.
Rault, S.
description The purpose of the present work is to develop nanoparticles of a new antitubulin agent of the family of tripentones by means of a phase inversion process. Dynamic light scattering, transmission electron microscopy and ζ-potential measurements were used to characterize tripentone loaded nanoparticles. From interfacial tension measurements and from the study of the rheological interfacial properties of the tripentone at the Labrafac ®–Solutol ® interface, the fraction of tripentone initially present in Labrafac ® would stay in the oily core of nanocapsules. Moreover, the interpenetration of some tripentone molecules within the surfactant units helps to the stabilization of the formulated nanoparticles. The encapsulation efficiency was determined by high performance liquid chromatography (HPLC) and was found to be above 95%. In vitro release studies were carried out in blank nanoparticles containing phosphate buffer, pH 7.4, at 37 °C. The drug release kinetics was measured by HPLC. Antiproliferative activity studies on L1210 cells showed that the cytotoxic activity of tripentone was totally recovered after encapsulation of the antitubulin agent in lipid nanoparticles. This study shows that lipid nanocapsules could be a promising and effective carrier for tripentone delivery in the treatment of cancers.
doi_str_mv 10.1016/j.ijpharm.2006.04.007
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19458145</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517306003309</els_id><sourcerecordid>19458145</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-775089308f156c0bd49a6b3038a4150ef3844f4a27f4482aa5bdaca5e80e8d313</originalsourceid><addsrcrecordid>eNqFkMFu1DAQhi1ERZfCI4B8gRNJ7diOvSdUVRSQKvVSztasM6FeJXawHSreHpeN1COn0Wi-f2b0EfKOs5Yz3l8eW39cHiDNbcdY3zLZMqZfkB03WjRC6v4l2TGhTaO4Fufkdc5HVsGOi1fknPe6EzW3I_YmpnmdoPgYaBxpXnMBH3CgCSeEjDRAiAuk4t2EmU4Rhjp89OWBAi3JLxhKDPipdgEfKYQKQnCYKPysozfkbIQp49utXpAfN1_ur781t3dfv19f3TZOdrI0Witm9oKZkavescMg99AfBBMGJFcMR2GkHCV0epTSdADqMIADhYahGQQXF-Tjae-S4q8Vc7Gzzw6nCQLGNVu-l8pwqSqoTqBLMeeEo12SnyH9sZzZJ7P2aDez9smsZdJWszX3fjuwHmYcnlObygp82ADIDqYxVQs-P3OGdXr_79PPJw6rjt8ek83OYzU2-ISu2CH6_7zyF5vsmi4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19458145</pqid></control><display><type>article</type><title>Formulation of sustained release nanoparticles loaded with a tripentone, a new anticancer agent</title><source>ScienceDirect Journals</source><creator>Malzert-Fréon, A. ; Vrignaud, S. ; Saulnier, P. ; Lisowski, V. ; Benoît, J.P. ; Rault, S.</creator><creatorcontrib>Malzert-Fréon, A. ; Vrignaud, S. ; Saulnier, P. ; Lisowski, V. ; Benoît, J.P. ; Rault, S.</creatorcontrib><description>The purpose of the present work is to develop nanoparticles of a new antitubulin agent of the family of tripentones by means of a phase inversion process. Dynamic light scattering, transmission electron microscopy and ζ-potential measurements were used to characterize tripentone loaded nanoparticles. From interfacial tension measurements and from the study of the rheological interfacial properties of the tripentone at the Labrafac ®–Solutol ® interface, the fraction of tripentone initially present in Labrafac ® would stay in the oily core of nanocapsules. Moreover, the interpenetration of some tripentone molecules within the surfactant units helps to the stabilization of the formulated nanoparticles. The encapsulation efficiency was determined by high performance liquid chromatography (HPLC) and was found to be above 95%. In vitro release studies were carried out in blank nanoparticles containing phosphate buffer, pH 7.4, at 37 °C. The drug release kinetics was measured by HPLC. Antiproliferative activity studies on L1210 cells showed that the cytotoxic activity of tripentone was totally recovered after encapsulation of the antitubulin agent in lipid nanoparticles. This study shows that lipid nanocapsules could be a promising and effective carrier for tripentone delivery in the treatment of cancers.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2006.04.007</identifier><identifier>PMID: 16723200</identifier><identifier>CODEN: IJPHDE</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Animals ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Biological and medical sciences ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Chemistry, Pharmaceutical ; Chromatography, High Pressure Liquid ; Colloids ; Cytotoxic activity ; Delayed-Action Preparations ; Drug Carriers ; Feasibility Studies ; General pharmacology ; Inhibitory Concentration 50 ; Interfacial tension measurements ; Lipid nanoparticles ; Medical sciences ; Mice ; Nanoparticles ; Particle Size ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Polyethylene Glycols - chemistry ; Pyrrolizidine Alkaloids - chemistry ; Pyrrolizidine Alkaloids - pharmacology ; Rheology ; Solubility ; Stearic Acids - chemistry ; Surface Tension ; Time Factors ; Triglycerides - chemistry ; Tripentones ; Tubulin Modulators - chemistry ; Tubulin Modulators - pharmacology</subject><ispartof>International journal of pharmaceutics, 2006-08, Vol.320 (1), p.157-164</ispartof><rights>2006 Elsevier B.V.</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-775089308f156c0bd49a6b3038a4150ef3844f4a27f4482aa5bdaca5e80e8d313</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18027931$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16723200$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Malzert-Fréon, A.</creatorcontrib><creatorcontrib>Vrignaud, S.</creatorcontrib><creatorcontrib>Saulnier, P.</creatorcontrib><creatorcontrib>Lisowski, V.</creatorcontrib><creatorcontrib>Benoît, J.P.</creatorcontrib><creatorcontrib>Rault, S.</creatorcontrib><title>Formulation of sustained release nanoparticles loaded with a tripentone, a new anticancer agent</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>The purpose of the present work is to develop nanoparticles of a new antitubulin agent of the family of tripentones by means of a phase inversion process. Dynamic light scattering, transmission electron microscopy and ζ-potential measurements were used to characterize tripentone loaded nanoparticles. From interfacial tension measurements and from the study of the rheological interfacial properties of the tripentone at the Labrafac ®–Solutol ® interface, the fraction of tripentone initially present in Labrafac ® would stay in the oily core of nanocapsules. Moreover, the interpenetration of some tripentone molecules within the surfactant units helps to the stabilization of the formulated nanoparticles. The encapsulation efficiency was determined by high performance liquid chromatography (HPLC) and was found to be above 95%. In vitro release studies were carried out in blank nanoparticles containing phosphate buffer, pH 7.4, at 37 °C. The drug release kinetics was measured by HPLC. Antiproliferative activity studies on L1210 cells showed that the cytotoxic activity of tripentone was totally recovered after encapsulation of the antitubulin agent in lipid nanoparticles. This study shows that lipid nanocapsules could be a promising and effective carrier for tripentone delivery in the treatment of cancers.</description><subject>Animals</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Chemistry, Pharmaceutical</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Colloids</subject><subject>Cytotoxic activity</subject><subject>Delayed-Action Preparations</subject><subject>Drug Carriers</subject><subject>Feasibility Studies</subject><subject>General pharmacology</subject><subject>Inhibitory Concentration 50</subject><subject>Interfacial tension measurements</subject><subject>Lipid nanoparticles</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Nanoparticles</subject><subject>Particle Size</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Polyethylene Glycols - chemistry</subject><subject>Pyrrolizidine Alkaloids - chemistry</subject><subject>Pyrrolizidine Alkaloids - pharmacology</subject><subject>Rheology</subject><subject>Solubility</subject><subject>Stearic Acids - chemistry</subject><subject>Surface Tension</subject><subject>Time Factors</subject><subject>Triglycerides - chemistry</subject><subject>Tripentones</subject><subject>Tubulin Modulators - chemistry</subject><subject>Tubulin Modulators - pharmacology</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqFkMFu1DAQhi1ERZfCI4B8gRNJ7diOvSdUVRSQKvVSztasM6FeJXawHSreHpeN1COn0Wi-f2b0EfKOs5Yz3l8eW39cHiDNbcdY3zLZMqZfkB03WjRC6v4l2TGhTaO4Fufkdc5HVsGOi1fknPe6EzW3I_YmpnmdoPgYaBxpXnMBH3CgCSeEjDRAiAuk4t2EmU4Rhjp89OWBAi3JLxhKDPipdgEfKYQKQnCYKPysozfkbIQp49utXpAfN1_ur781t3dfv19f3TZOdrI0Witm9oKZkavescMg99AfBBMGJFcMR2GkHCV0epTSdADqMIADhYahGQQXF-Tjae-S4q8Vc7Gzzw6nCQLGNVu-l8pwqSqoTqBLMeeEo12SnyH9sZzZJ7P2aDez9smsZdJWszX3fjuwHmYcnlObygp82ADIDqYxVQs-P3OGdXr_79PPJw6rjt8ek83OYzU2-ISu2CH6_7zyF5vsmi4</recordid><startdate>20060831</startdate><enddate>20060831</enddate><creator>Malzert-Fréon, A.</creator><creator>Vrignaud, S.</creator><creator>Saulnier, P.</creator><creator>Lisowski, V.</creator><creator>Benoît, J.P.</creator><creator>Rault, S.</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20060831</creationdate><title>Formulation of sustained release nanoparticles loaded with a tripentone, a new anticancer agent</title><author>Malzert-Fréon, A. ; Vrignaud, S. ; Saulnier, P. ; Lisowski, V. ; Benoît, J.P. ; Rault, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-775089308f156c0bd49a6b3038a4150ef3844f4a27f4482aa5bdaca5e80e8d313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Chemistry, Pharmaceutical</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Colloids</topic><topic>Cytotoxic activity</topic><topic>Delayed-Action Preparations</topic><topic>Drug Carriers</topic><topic>Feasibility Studies</topic><topic>General pharmacology</topic><topic>Inhibitory Concentration 50</topic><topic>Interfacial tension measurements</topic><topic>Lipid nanoparticles</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Nanoparticles</topic><topic>Particle Size</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Polyethylene Glycols - chemistry</topic><topic>Pyrrolizidine Alkaloids - chemistry</topic><topic>Pyrrolizidine Alkaloids - pharmacology</topic><topic>Rheology</topic><topic>Solubility</topic><topic>Stearic Acids - chemistry</topic><topic>Surface Tension</topic><topic>Time Factors</topic><topic>Triglycerides - chemistry</topic><topic>Tripentones</topic><topic>Tubulin Modulators - chemistry</topic><topic>Tubulin Modulators - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Malzert-Fréon, A.</creatorcontrib><creatorcontrib>Vrignaud, S.</creatorcontrib><creatorcontrib>Saulnier, P.</creatorcontrib><creatorcontrib>Lisowski, V.</creatorcontrib><creatorcontrib>Benoît, J.P.</creatorcontrib><creatorcontrib>Rault, S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Malzert-Fréon, A.</au><au>Vrignaud, S.</au><au>Saulnier, P.</au><au>Lisowski, V.</au><au>Benoît, J.P.</au><au>Rault, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Formulation of sustained release nanoparticles loaded with a tripentone, a new anticancer agent</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2006-08-31</date><risdate>2006</risdate><volume>320</volume><issue>1</issue><spage>157</spage><epage>164</epage><pages>157-164</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><coden>IJPHDE</coden><abstract>The purpose of the present work is to develop nanoparticles of a new antitubulin agent of the family of tripentones by means of a phase inversion process. Dynamic light scattering, transmission electron microscopy and ζ-potential measurements were used to characterize tripentone loaded nanoparticles. From interfacial tension measurements and from the study of the rheological interfacial properties of the tripentone at the Labrafac ®–Solutol ® interface, the fraction of tripentone initially present in Labrafac ® would stay in the oily core of nanocapsules. Moreover, the interpenetration of some tripentone molecules within the surfactant units helps to the stabilization of the formulated nanoparticles. The encapsulation efficiency was determined by high performance liquid chromatography (HPLC) and was found to be above 95%. In vitro release studies were carried out in blank nanoparticles containing phosphate buffer, pH 7.4, at 37 °C. The drug release kinetics was measured by HPLC. Antiproliferative activity studies on L1210 cells showed that the cytotoxic activity of tripentone was totally recovered after encapsulation of the antitubulin agent in lipid nanoparticles. This study shows that lipid nanocapsules could be a promising and effective carrier for tripentone delivery in the treatment of cancers.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>16723200</pmid><doi>10.1016/j.ijpharm.2006.04.007</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0378-5173
ispartof International journal of pharmaceutics, 2006-08, Vol.320 (1), p.157-164
issn 0378-5173
1873-3476
language eng
recordid cdi_proquest_miscellaneous_19458145
source ScienceDirect Journals
subjects Animals
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Biological and medical sciences
Cell Line, Tumor
Cell Proliferation - drug effects
Chemistry, Pharmaceutical
Chromatography, High Pressure Liquid
Colloids
Cytotoxic activity
Delayed-Action Preparations
Drug Carriers
Feasibility Studies
General pharmacology
Inhibitory Concentration 50
Interfacial tension measurements
Lipid nanoparticles
Medical sciences
Mice
Nanoparticles
Particle Size
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Polyethylene Glycols - chemistry
Pyrrolizidine Alkaloids - chemistry
Pyrrolizidine Alkaloids - pharmacology
Rheology
Solubility
Stearic Acids - chemistry
Surface Tension
Time Factors
Triglycerides - chemistry
Tripentones
Tubulin Modulators - chemistry
Tubulin Modulators - pharmacology
title Formulation of sustained release nanoparticles loaded with a tripentone, a new anticancer agent
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T19%3A45%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Formulation%20of%20sustained%20release%20nanoparticles%20loaded%20with%20a%20tripentone,%20a%20new%20anticancer%20agent&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Malzert-Fr%C3%A9on,%20A.&rft.date=2006-08-31&rft.volume=320&rft.issue=1&rft.spage=157&rft.epage=164&rft.pages=157-164&rft.issn=0378-5173&rft.eissn=1873-3476&rft.coden=IJPHDE&rft_id=info:doi/10.1016/j.ijpharm.2006.04.007&rft_dat=%3Cproquest_cross%3E19458145%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c424t-775089308f156c0bd49a6b3038a4150ef3844f4a27f4482aa5bdaca5e80e8d313%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=19458145&rft_id=info:pmid/16723200&rfr_iscdi=true